Home > News & Insight > Private Equity News

News & Insight

Tuesday, August 04, 2015
Palisade Capital Completes the Sale of PCEPII Portfolio Company Shoe Sensation
Posted in Private Equity News: Palisade Capital Management, LLC today announced that it sold a majority interest in Shoe Sensation, a leading family footwear retailer in the Midwestern United States, to J.W. Childs Associates, L.P. Financial terms of the investment were not disclosed. “Shoe Sensation has experienced over six consecutive years of comparable store revenue growth and, since 2010, has grown from 62 locations in 10 states to 115 stores in 17 states,” said Jeffrey Serkes, Chief Operating Officer of Palisade Capital. “It has been a pleasure working with the company’s management team over the past several years, as both they and Shoe Sensation’s employees have built a terrific culture that has the company poised for continued success.”

Wednesday, April 01, 2015
PCEP II Portfolio Company Brickell Biotech, Inc. Signs Exclusive License and Development Agreement for BBI-4000 with Kaken Pharmaceutical Co., Ltd.
Posted in Private Equity News: Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet medical needs in the global dermatology markets, today announced the signing of an exclusive license and development agreement for BBI-4000 with Kaken Pharmaceutical Co., Ltd. (“Kaken”), a top-tier specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel dermatological drugs.

Tuesday, February 03, 2015
PCEPII Portfolio Company Brickell Biotech Announces $10M Series C Financing, Initiates Phase 2b Study of BBI-4000 in Patients with Axillary Hyperhidrosis, and Acquires Novel, Clinical-Stage Compound for the Oral Treatment of Atopic Dermatitis
Posted in Private Equity News: Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet medical needs in the global dermatology markets, today announced a $10 million Series C financing round (the “Offering”). Brickell’s pipeline includes new molecular entities in dermatology for hyperhidrosis, atopic dermatitis, and acne.

Wednesday, November 19, 2014
PPPII Portfolio Company QualityHealth Acquired by Sharecare
Posted in Private Equity News: Sharecare, a comprehensive health and wellness engagement platform, today announced the acquisition of QualityHealth, a platform for identifying patients at large scale, and activating them to take relevant health-specific actions. As one of the industry’s largest permission-based databases, QualityHealth has more than 50 million registered members and touches 100 million health consumers each month across 175 different health, wellness and therapeutic categories. PPPII will continue to own Sharecare equity post-closing.

Tuesday, September 30, 2014
PCEPII Portfolio Company Shoe Sensation Growing Headquarters and Distribution Center in Clark County
Posted in Private Equity News: Shoe Sensation, Inc., a regional chain of family shoe stores, announced plans today to expand its corporate headquarters and distribution center in Clark County, creating up to 32 new jobs by 2017.

Monday, September 29, 2014
PCEPII Portfolio Company Mitralign Confirms First-In-Man Percutaneous Tricuspid Repair: Non-surgical option for tricuspid regurgitation could benefit 1.6 million U.S. patients
Posted in Private Equity News: Mitralign Inc., a cardiovascular device company, today reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR).

1 2 3 >

Monday, November 21, 2022
Short Duration Convertible Bonds: A Compelling Alternative to Traditional Fixed Income: The U.S. Federal Reserve’s fight against inflation through increases in the Fed Funds rate and quantitative tightening has led to the worst year on record for the U.S. fixed income markets (as measured by Bloomberg U.S. Aggregate Bond Index performance of -15.7% year-to-date through October 31, 2022). This environment, when combined with the potential for additional rate hikes, has resulted in significant losses to fixed income portfolios.; Find Out More and Request This White Paper